443 results on '"Balsano, Clara"'
Search Results
2. Myosteatosis is closely associated with sarcopenia and significantly worse outcomes in patients with cirrhosis
3. Sarcopenia, a condition shared by various diseases: can we alleviate or delay the progression?
4. Fall of viral and bacterial pneumonia hospitalizations following COVID-19 pandemic mitigation strategies: a central Italian Region retrospective study
5. The Covid-19 Decision Support System (C19DSS) – A Mobile App
6. Application of machine learning approach in emergency department to support clinical decision making for SARS-CoV-2 infected patients
7. Artificial Intelligence and liver: Opportunities and barriers
8. The Covid-19 Decision Support System (C19DSS) – A Mobile App
9. PaO2/FiO2 ratio forecasts COVID-19 patients’ outcome regardless of age: a cross-sectional, monocentric study
10. Correction to: Focal adhesion kinase inhibitor TAE226 combined with Sorafenib slows down hepatocellular carcinoma by multiple epigenetic effects
11. Copper-catalyzed dicarbonyl stress in NAFLD mice: protective effects of Oleuropein treatment on liver damage
12. The application of artificial intelligence in hepatology: A systematic review
13. Copper concentrations are prevalently associated with antithrombin III, but also with prothrombin time and fibrinogen in patients with liver cirrhosis: A cross-sectional retrospective study
14. Myosteatosis is closely associated with sarcopenia and significantly worse outcomes in patients with cirrhosis
15. Author's reply: The importance of professional training to foster the implementation of Artificial Intelligence in the clinical setting of liver diseases
16. Oleuropein overrides liver damage in steatotic mice
17. Focal adhesion kinase inhibitor TAE226 combined with Sorafenib slows down hepatocellular carcinoma by multiple epigenetic effects
18. The Role of Epigenetic Control of Mitochondrial (Dys)Function in MASLD Onset and Progression
19. Artificial Intelligence and liver: Opportunities and barriers
20. Untargeted metabolomics as a diagnostic tool in NAFLD: discrimination of steatosis, steatohepatitis and cirrhosis
21. Salivary analytical device (SAD) a good tool for monitoring the metabolic status of patients with fatty liver disease
22. Fully automated approach of machine learning combined with deep learning to forecast the coronary artery disease in patients with non-alcoholic fatty liver disease
23. Gastrointestinal peptides and nonalcoholic fatty liver disease
24. The Hepatitis B Virus X Gene Induces p53-Mediated Programmed Cell Death
25. Activation of SAPK/JNK by TNF Receptor 1 Through a Noncytotoxic TRAF2- Dependent Pathway
26. AISF position paper on liver transplantation and pregnancy: Women in Hepatology Group, Italian Association for the Study of the Liver (AISF)
27. Profiling of cell‐free DNA methylation and histone signatures in pediatric NAFLD: A pilot study
28. Evaluation of tolerance to ambulatory blood pressure monitoring: Analysis of dipping profile in a large cohort of hypertensive patients
29. Core domain mutant Y220C of p53 protein has a key role in copper homeostasis in case of free fatty acids overload
30. Alteration of Inflammatory Parameters and Psychological Post-Traumatic Syndrome in Long-COVID Patients
31. Probiotics in non-alcoholic fatty liver disease: which and when
32. Inverse correlation between plasma oxysterol and LDL-cholesterol levels in hepatitis C virus-infected patients
33. Children and Adolescents Dietary Habits and Lifestyle Changes during COVID-19 Lockdown in Italy
34. Additional file 2 of Correction to: Focal adhesion kinase inhibitor TAE226 combined with Sorafenib slows down hepatocellular carcinoma by multiple epigenetic effects
35. Additional file 1 of Correction to: Focal adhesion kinase inhibitor TAE226 combined with Sorafenib slows down hepatocellular carcinoma by multiple epigenetic effects
36. Additional file 1 of Copper-catalyzed dicarbonyl stress in NAFLD mice: protective effects of Oleuropein treatment on liver damage
37. Additional file 3 of Correction to: Focal adhesion kinase inhibitor TAE226 combined with Sorafenib slows down hepatocellular carcinoma by multiple epigenetic effects
38. An Ontology of Medical Wearables
39. It Is High Time Physicians Thought of Natural Products for Alleviating NAFLD. Is There Sufficient Evidence to Use Them?
40. The AP1 Transcription Factor as a Model to Study the Modulation of Intracellular Signalling Pathways by the Hepatitis B Virus Transactivator pX
41. The hepatitis B virus X gene product transactivates the HIV-LTR in vivo
42. Detection of replicative intermediates of viral RNA in peripheral blood mononuclear cells from chronic hepatitis C virus carriers
43. PaO2/FiO2 ratio forecasts COVID-19 patients’ outcome regardless of age: a cross-sectional, monocentric study
44. Focal adhesion kinase inhibitor TAE226 combined with Sorafenib slows down hepatocellular carcinoma by multiple epigenetics effects
45. Laboratory parameters related to severe disease and death in SARS‐CoV‐2 pneumonia: Retrospective analysis
46. Additional file 7 of Focal adhesion kinase inhibitor TAE226 combined with Sorafenib slows down hepatocellular carcinoma by multiple epigenetic effects
47. Additional file 6 of Focal adhesion kinase inhibitor TAE226 combined with Sorafenib slows down hepatocellular carcinoma by multiple epigenetic effects
48. Additional file 10 of Focal adhesion kinase inhibitor TAE226 combined with Sorafenib slows down hepatocellular carcinoma by multiple epigenetic effects
49. EMOTIONAL SUPPORT FROM THE SOCIAL ROBOT NAO AT A PEDIATRIC EMERGENCY DEPARTMENT
50. Additional file 2 of Focal adhesion kinase inhibitor TAE226 combined with Sorafenib slows down hepatocellular carcinoma by multiple epigenetic effects
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.